Clinical trial
Azacitidine in Treating Patients With Myelofibrosis
NCT00381693 · Mayo Clinic, Other · Terminated
Key facts
| NCT number | NCT00381693 |
|---|---|
| Title | Azacitidine in Treating Patients With Myelofibrosis |
| Official title | Phase II Study of Azacitidine in Myelofibrosis |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myeloproliferative Disorders, Secondary Myelofibrosis |
| Intervention type | Drug |
| Interventions | azacitidine |
| Enrollment | 10 |
| Start date | Aug 1, 2006 |
| Primary completion | Mar 1, 2008 |
| Completion | Apr 1, 2009 |
| First posted | Sep 28, 2006 |
| Last update posted | Apr 21, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: